PE20230091A1 - Conjugados terapeuticos - Google Patents
Conjugados terapeuticosInfo
- Publication number
- PE20230091A1 PE20230091A1 PE2022000435A PE2022000435A PE20230091A1 PE 20230091 A1 PE20230091 A1 PE 20230091A1 PE 2022000435 A PE2022000435 A PE 2022000435A PE 2022000435 A PE2022000435 A PE 2022000435A PE 20230091 A1 PE20230091 A1 PE 20230091A1
- Authority
- PE
- Peru
- Prior art keywords
- kinase
- conjugate
- pseudokinase
- pi3k
- fcb
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
Abstract
Referido a un conjugado terapeutico caracterizado porque forma un enlace covalente con una quinasa, particularmente PI3-quinasa (PI3K), o pseudoquinasa. En donde el conjugado tiene la siguiente estructura: (FCB)a-(L)b-(CLM)c, en donde a y c son independientemente numeros enteros de entre 1 y 5, b entre 0 y 5, la porcion FCB comprende un inhibidor de PI3K, o fragmento, analogo o derivado de este. Tambien se refiere a una composicion farmaceutica que comprende dicho conjugado y un metodo para regular la actividad de la quinasa o pseudoquinasa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962902554P | 2019-09-19 | 2019-09-19 | |
US202063078055P | 2020-09-14 | 2020-09-14 | |
PCT/US2020/051491 WO2021055747A1 (en) | 2019-09-19 | 2020-09-18 | Therapeutic conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230091A1 true PE20230091A1 (es) | 2023-01-16 |
Family
ID=74883745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000435A PE20230091A1 (es) | 2019-09-19 | 2020-09-18 | Conjugados terapeuticos |
Country Status (16)
Country | Link |
---|---|
US (3) | US20220387603A1 (es) |
EP (1) | EP4031143A4 (es) |
JP (1) | JP2022548135A (es) |
KR (1) | KR20220079866A (es) |
CN (1) | CN114599366A (es) |
AU (1) | AU2020349543A1 (es) |
BR (1) | BR112022005026A2 (es) |
CA (1) | CA3154079A1 (es) |
CL (1) | CL2022000665A1 (es) |
CO (1) | CO2022003703A2 (es) |
IL (1) | IL291486A (es) |
MX (1) | MX2022003217A (es) |
PE (1) | PE20230091A1 (es) |
TW (1) | TW202126307A (es) |
WO (1) | WO2021055747A1 (es) |
ZA (1) | ZA202203201B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4031143A4 (en) | 2019-09-19 | 2023-11-01 | Totus Medicines Inc. | THERAPEUTIC CONJUGATES |
WO2022198024A1 (en) * | 2021-03-18 | 2022-09-22 | Totus Medicines Inc. | Therapeutic conjugates |
WO2023179771A1 (en) | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof |
WO2023183936A2 (en) * | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
MX2010001650A (es) | 2007-08-10 | 2010-08-02 | Glaxosmithkline Llc | Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales. |
EP3311818A3 (en) * | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
AU2010292198A1 (en) * | 2009-09-09 | 2012-04-05 | Celgene Avilomics Research, Inc. | PI3 kinase inhibitors and uses thereof |
ES2627703T3 (es) | 2010-01-22 | 2017-07-31 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Inhibidores de PI3·quinasa |
US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
BR112012029994A2 (pt) | 2010-05-28 | 2019-09-24 | Biocryst Pharm Inc | composto heterocíclicos como inibidores de janus quinase |
US20120231963A1 (en) | 2011-03-10 | 2012-09-13 | Raybiotech, Inc, | Biotin-label-based antibody array for high-content profiling of protein expression |
KR102052670B1 (ko) * | 2011-05-17 | 2019-12-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키나아제 저해제 |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
US9724352B2 (en) * | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
CN102675323B (zh) | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 |
AU2015276264B2 (en) | 2014-06-17 | 2018-12-20 | Chiesi Farmaceutici S.P.A. | Indolizine derivatives as phosphoinositide 3-kinases inhibitors |
CA2960824A1 (en) * | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
CN109111447A (zh) * | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途 |
US20200283444A1 (en) | 2017-08-02 | 2020-09-10 | Northwestern University | Substituted fused pyrimidine compounds and uses thereof |
WO2019113523A1 (en) | 2017-12-08 | 2019-06-13 | Ashok Bajji | Compounds and therapeutic uses thereof |
CN109081905A (zh) | 2018-08-03 | 2018-12-25 | 浩力森涂料(上海)有限公司 | 水性环氧固化剂及其制备方法 |
EP3849556A1 (en) | 2018-09-13 | 2021-07-21 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Modulation of trf1 for brain cancer treatment |
WO2020243457A1 (en) | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
EP4031143A4 (en) | 2019-09-19 | 2023-11-01 | Totus Medicines Inc. | THERAPEUTIC CONJUGATES |
US20230312577A1 (en) | 2020-06-05 | 2023-10-05 | Monash University | Dual kinase-bromodomain inhibitors |
-
2020
- 2020-09-18 EP EP20865745.2A patent/EP4031143A4/en active Pending
- 2020-09-18 WO PCT/US2020/051491 patent/WO2021055747A1/en unknown
- 2020-09-18 TW TW109132462A patent/TW202126307A/zh unknown
- 2020-09-18 CN CN202080074001.4A patent/CN114599366A/zh active Pending
- 2020-09-18 BR BR112022005026A patent/BR112022005026A2/pt unknown
- 2020-09-18 MX MX2022003217A patent/MX2022003217A/es unknown
- 2020-09-18 AU AU2020349543A patent/AU2020349543A1/en active Pending
- 2020-09-18 US US17/642,945 patent/US20220387603A1/en active Pending
- 2020-09-18 JP JP2022516684A patent/JP2022548135A/ja active Pending
- 2020-09-18 PE PE2022000435A patent/PE20230091A1/es unknown
- 2020-09-18 KR KR1020227012813A patent/KR20220079866A/ko unknown
- 2020-09-18 CA CA3154079A patent/CA3154079A1/en active Pending
-
2022
- 2022-03-14 US US17/694,592 patent/US11484597B2/en active Active
- 2022-03-17 ZA ZA2022/03201A patent/ZA202203201B/en unknown
- 2022-03-18 IL IL291486A patent/IL291486A/en unknown
- 2022-03-18 CL CL2022000665A patent/CL2022000665A1/es unknown
- 2022-03-28 CO CONC2022/0003703A patent/CO2022003703A2/es unknown
- 2022-09-28 US US17/955,182 patent/US20230096658A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022548135A (ja) | 2022-11-16 |
EP4031143A1 (en) | 2022-07-27 |
BR112022005026A2 (pt) | 2022-06-21 |
KR20220079866A (ko) | 2022-06-14 |
MX2022003217A (es) | 2022-06-29 |
US20220387603A1 (en) | 2022-12-08 |
CN114599366A (zh) | 2022-06-07 |
ZA202203201B (en) | 2023-11-29 |
TW202126307A (zh) | 2021-07-16 |
US11484597B2 (en) | 2022-11-01 |
EP4031143A4 (en) | 2023-11-01 |
AU2020349543A1 (en) | 2022-03-24 |
CA3154079A1 (en) | 2021-03-25 |
CO2022003703A2 (es) | 2022-07-08 |
US20220211855A1 (en) | 2022-07-07 |
US20230096658A1 (en) | 2023-03-30 |
IL291486A (en) | 2022-05-01 |
WO2021055747A1 (en) | 2021-03-25 |
CL2022000665A1 (es) | 2022-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230091A1 (es) | Conjugados terapeuticos | |
AR126205A2 (es) | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario | |
CY1109877T1 (el) | Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
CY1121593T1 (el) | Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων | |
CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
AR048833A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
AR055810A1 (es) | Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta | |
CO6361938A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional | |
CO6382133A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional | |
BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
AR100562A1 (es) | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal | |
AR085173A1 (es) | Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas | |
CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
ATE287267T1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
AR112482A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry |